高级检索
当前位置: 首页 > 详情页

Paeoniflorin promotes intestinal stem cell-mediated epithelial regeneration and repair via PI3K-AKT-mTOR signalling in ulcerative colitis

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Hebei Univ Chinese Med, Affiliated Hosp 1, Shijiazhuang, Peoples R China [2]Xingtai Med Coll, Xingtai, Peoples R China [3]Hebei Univ Chinese Med, Shijiazhuang, Peoples R China [4]Hebei Univ Chinese Med, Affiliated Hosp 1, 389, Zhongshan Rd, Shijiazhuang 050011, Hebei, Peoples R China
出处:
ISSN:

关键词: Ulcerative colitis Paeoniflorin Colon organoids Intestinal stem cells (ISCs) PI3K-AKT-mTOR

摘要:
Ulcerative colitis (UC) is a chronic and immune-mediated inflammatory disorder characterized by abdominal pain, diarrhoea, and haematochezia. The goal of clinical therapy for UC is mucosal healing, accomplished regenerating and repairing the intestinal epithelium. Paeoniflorin (PF) is a natural ingredient extracted from Paeonia lactiflora that has significant anti-inflammatory and immunoregulatory efficacy. In this study, investigated how PF could regulate the renewal and differentiation of intestinal stem cells (ISCs) to improve the regeneration and repair of the intestinal epithelium in UC. Our experimental results showed that PF significantly alleviated colitis induced by dextran sulfate sodium (DSS) and ameliorated intestinal mucosal injury by regu-lating the renewal and differentiation of ISCs. The mechanism by which PF regulates ISCs was confirmed to through PI3K-AKT-mTOR signalling. In vitro, we found that PF not only improved the growth of TNF-alpha-induced colon organoids but also increased the expression of genes and proteins related to the differentiation and regeneration of ISCs. Furthermore, PF promoted the repair ability of lipopolysaccharide (LPS)-induced IEC-6 cells. The mechanism by which PF regulates ISCs was further confirmed and was consistent with the in vivo results. Overall, these findings demonstrate that PF accelerates epithelial regeneration and repair by promoting the renewal and differentiation of ISCs, suggesting that PF treatment may be beneficial to mucosal healing in patients.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 2 区 医学
小类 | 2 区 药学 3 区 免疫学
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 药学 3 区 免疫学
JCR分区:
出版当年[2023]版:
Q1 PHARMACOLOGY & PHARMACY Q2 IMMUNOLOGY
最新[2023]版:
Q1 PHARMACOLOGY & PHARMACY Q2 IMMUNOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者:
第一作者机构: [1]Hebei Univ Chinese Med, Affiliated Hosp 1, Shijiazhuang, Peoples R China [3]Hebei Univ Chinese Med, Shijiazhuang, Peoples R China
通讯作者:
通讯机构: [1]Hebei Univ Chinese Med, Affiliated Hosp 1, Shijiazhuang, Peoples R China [4]Hebei Univ Chinese Med, Affiliated Hosp 1, 389, Zhongshan Rd, Shijiazhuang 050011, Hebei, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:15101 今日访问量:2 总访问量:962 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北大学附属医院 技术支持:重庆聚合科技有限公司 地址:保定市莲池区裕华东路212号